Join the club for FREE to access the whole archive and other member benefits.

AgeX Therapeutics

Biotechnology company focused on the development of novel therapeutics for age-related degenerative disease

AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte™ technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology.

Key highlights

March-2023: Received a $10,000,000 loan from Juvenescence to acquire Serina Therapeutics Inc. Plans to spinoff of its subsidiary Reverse Bioengineering. Michael West stepping down as CEO of AgeX but will continue as CEO of Reverse Bio.

Visit website:





Details last updated 02-Oct-2019

People at AgeX Therapeutics

Dana Larocca

VP of Discovery Research

Michael D. West

Dr Michael D West is the founder and CEO of AgeX Therapeutics

AgeX Therapeutics News

AgeX credit running out with substantial doubt it can continue

FierceBiotech - 15-Aug-2022

Let's hope their research is either successful for the company or its successors


Merger between regeneration companies AgeX and LyGenesis not going ahead

Business Wire - 23-Jul-2021

Both companies to continue with the diverse technologies and product development


Orion College ageing research receives 1 million UK pounds from Jim Mellon (LEAF) - 18-May-2020

He believes in the importance of boosting immunoresilience among elderly


Stem cells from a 110-year-old women open doors to aging research - 20-Mar-2020

Scientists created stem cells from supercentenarian for the first time, calling it "super sauce"


Donor supercentenarian’s cells help unlock mysteries of super-longevity

Longevity Technology - 28-Feb-2020

Evidence of cellular age reversal demonstrated in this gateway research


Fight Aging! reports back from SENS Research Foundation Pitch Day

Fight Aging! - 20-Jan-2020

When some of these succeed in human trials even more money will pile in to fund further advances


Method of Generating Induced Pluripotent Stem Cells

Longevity Technology - 10-Dec-2019

New reprogramming technology could provide an alternate source of material needed for therapies


LEAF interviews AgeX Therapeutics CEO Dr. Michael West (LEAF) - 30-Sep-2019

May only be a few years away from implementing induced tissue regeneration in humans


Michael West examines how to safely revive telomerase (LEAF) - 12-Sep-2019

It powers foetal development and telomere length, but also cancers


Today's 50 year-olds may live another 100 years

Forbes - 26-Aug-2019

Good summary of some major investments in life extension companies


Aubrey de Grey shortens timeframe for human rejuvenation

Next Big Future - 28-Feb-2019

Once proven in mice, demand and funding will surge


AgeX Identifies Genes Implicated in Regeneration and Cancer

Business Wire - 02-Jan-2018

Study that reveals genes implicated in tissue regeneration, cancer, and aging. Worked in collabo...

Topics mentioned on this page:
Regenerative Medicine